Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Pharmaceutical Industry stories

Nov 16, 2026

FDA approves Roche's oral breast cancer pill Wilserdly

The FDA approved Roche's oral treatment for estrogen receptor-positive, HER2-negative advanced breast cancer, providing a new option for patients and a significant commercial boost for the Swiss drugmaker.

Nov 16, 2026·3 sources
00

Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push

Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to expand development of treatments for rare blood cancers known as myeloproliferative neoplasms, its 14th or 15th acquisition of 2026.

Nov 16, 2026·3 sources
00

Sofinnova Partners raises €725M crossover fund for late-stage European biotechs

Paris-based Sofinnova Partners secured €725 million ($815 million) for its second crossover fund targeting late-stage European biopharma companies, addressing a financing gap in the sector.

Nov 16, 2026·3 sources
00
Nov 15, 2026

J&J in talks to acquire eye disease biotech for up to $3.4bn

Johnson & Johnson is poised to acquire a privately held eye disease drug developer in a deal valued at up to $3.4 billion, according to the Financial Times.

Nov 15, 2026·2 sources
00
Nov 13, 2026

AstraZeneca cuts 600 US sales jobs in respiratory and immunology

AstraZeneca has eliminated approximately 600 positions from its US respiratory and immunology commercial teams as part of a three-year cost-savings initiative.

Nov 13, 2026·2 sources
00

Novo submits sickle cell drug for regulatory approval

Novo Nordisk has submitted a sickle cell disease drug for regulatory approval, a medicine acquired in a billion-dollar deal that the company views as a future blockbuster.

Nov 13, 2026·2 sources
00

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Swiss immune drug developer Windward Bio raised $175 million in its IPO, the biotech sector's 30th listing of the year, to advance lung disease drugs licensed from China.

Nov 13, 2026·2 sources
00
Nov 12, 2026

FDA quietly shelves Trump's drug fast-track voucher program amid agency chaos

No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.

Nov 12, 2026·2 sources
00
Nov 11, 2026

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.

Nov 11, 2026·3 sources
00

Amgen's Sjögren's drug cuts disease activity in trial

Amgen reported positive trial results showing its experimental drug reduced disease activity in patients with Sjögren's syndrome, a chronic autoimmune condition with limited treatment options.

Nov 11, 2026·2 sources
00
Nov 10, 2026

FDA approves Merck KGaA's pimicotinib for tenosynovial giant cell tumor

The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.

Nov 10, 2026·3 sources
00

AstraZeneca acquires vaccine biotech Omniose to bolster pipeline

AstraZeneca acquired early-stage US biotech Omniose, which is developing vaccines against serious bacterial infections, integrating it into its infectious diseases division.

Nov 10, 2026·2 sources
00
Nov 9, 2026

FDA approves Bayer's asundexian as first-in-class factor XIa inhibitor for stroke prevention

The FDA approved asundexian (Sunharbo), a novel blood thinner from Bayer, to reduce the risk of recurrent stroke in adults, marking the first approval in the factor XIa inhibitor class.

Nov 9, 2026·6 sources
00
Nov 6, 2026

GSK and Moderna settle patent dispute over COVID and RSV vaccines

GSK has settled lawsuits accusing Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, resolving a major intellectual property dispute between the two drugmakers.

Nov 6, 2026·2 sources
00

Novartis links two tumor cases in children to Zolgensma gene therapy

Novartis disclosed that two of nine reported tumor cases in Zolgensma recipients showed evidence of the viral delivery vector integrating into patient DNA, raising new safety questions for the gene therapy field.

Nov 6, 2026·3 sources
00

FDA launches investigation into Novartis' Zolgensma over cancer cases

The FDA is investigating a 'serious risk' of cancer linked to Novartis' spinal muscular atrophy gene therapy Zolgensma, following reports of tumor cases in children. This follows Novartis linking two tumor cases in children to the therapy.

Nov 6, 2026·2 sources
00

Moderna posts first quarterly profit in two years, raises revenue forecast

Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.

Nov 6, 2026·5 sources
00
Nov 5, 2026

Novartis reports nine tumor cases possibly linked to Zolgensma gene therapy

Novartis confirmed that nine patients who received its spinal muscular atrophy gene therapy Zolgensma have developed tumors following treatment, with seven cases newly reported, raising serious safety concerns about the widely used pediatric drug.

Nov 5, 2026·3 sources
00

Albertsons ordered to pay $900 million for fueling opioid epidemic in Washington state

A judge ruled that Albertsons must pay Washington state $900 million for failing through its pharmacies to prevent the misuse of addictive painkillers, contributing to the opioid epidemic.

Nov 5, 2026·2 sources
00

Amgen's Repatha linked to fewer heart attacks versus Zetia in new data

New data from Amgen showed its PCSK9 inhibitor Repatha reduced heart attack risk by approximately 20% more than Zetia (ezetimibe) in patients where statins are insufficient.

Nov 5, 2026·2 sources
00
Nov 4, 2026

AstraZeneca made $10 billion offer for obesity drugmaker Rhythm Pharmaceuticals

AstraZeneca made a $10 billion takeover offer for Rhythm Pharmaceuticals, which specializes in treatments for metabolic conditions and severe obesity, according to sources familiar with the matter.

Nov 4, 2026·2 sources
00

Sino Biopharmaceutical signs cancer deal worth up to $7 billion with Boehringer Ingelheim

Sino Biopharmaceutical entered an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate up to approximately $7 billion in total value.

Nov 4, 2026·3 sources
00

Novo Nordisk raises 2026 outlook for third time on strong Wegovy pill sales

Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.

Nov 4, 2026·4 sources
00
Nov 3, 2026

Ultragenyx to cut 20% of workforce after Wilson disease gene therapy failure

Ultragenyx Therapeutics announced plans to lay off approximately 20% of its employees and discontinue development of its Wilson disease gene therapy GTX-102 following a major setback in Angelman syndrome trials.

Nov 3, 2026·2 sources
00

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Servier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.

Nov 3, 2026·2 sources
00

Pfizer raises 2026 outlook on strong demand for non-Covid drugs

Pfizer raised its full-year profit and revenue outlook after third-quarter results beat estimates, driven by growing demand for newly launched and acquired medicines as Covid product sales decline.

Nov 3, 2026·4 sources
00

Bayer raises 2026 profit outlook on strong pharmaceutical demand

Bayer AG raised its annual profit outlook after better-than-expected third-quarter performance driven by demand for newer drugs in its pharmaceuticals business.

Nov 3, 2026·2 sources
00
Nov 2, 2026

Teva Pharmaceutical beats Q3 profit forecasts, raises 2026 revenue guidance

Israeli drugmaker Teva Pharmaceutical Industries reported third-quarter profit that exceeded analyst expectations, driven by strong sales of three branded medicines that offset declines in generic drugs. The company raised its full-year 2026 revenue estimates following the results.

Nov 2, 2026·3 sources
00

Fresenius signs biosimilars development agreement with WuXi Biologics

German healthcare company Fresenius has entered a partnership with China's WuXi Biologics to develop a pipeline of biosimilar drugs, expanding its presence in the biologics market.

Nov 2, 2026·3 sources
00
Oct 30, 2026

EMA reviews Lundbeck's Deanxit after reports of serious neurological side effects

The European Medicines Agency has begun a safety review of Deanxit, a depression and anxiety medication made by Danish drugmaker H Lundbeck, following reports of serious neurological and psychiatric side effects.

Oct 30, 2026·2 sources
00

AbbVie raises annual profit forecast on strong immunology drug sales

AbbVie raised its full-year profit forecast after beating third-quarter expectations, driven by strong demand for its newer immunology and neuroscience drugs as the company navigates the Humira patent cliff.

Oct 30, 2026·2 sources
00
Oct 28, 2026

Genmab's petosemtamab cuts death risk by half in head and neck cancer trial

Danish drugmaker Genmab reported its experimental drug petosemtamab reduced the risk of death by 50% in a late-stage study of patients with head and neck cancer, sending US-traded shares up 28%.

Oct 28, 2026·3 sources
00

GSK shares fall after vaccine sales disappoint in Q3 results

GSK reported a drop in vaccine sales in its third quarter, sending shares down despite beating overall sales and profit expectations, as the UK drugmaker works to accelerate growth and prepare for patent expirations.

Oct 28, 2026·4 sources
00
Oct 27, 2026

FDA warns Amgen over misleading Vectibix cancer drug promotional video

The US FDA warned Amgen that a promotional video for its colorectal cancer drug Vectibix was misleading because it highlighted benefits while failing to adequately disclose serious safety risks and patient limitations. The warning letter was issued on Tuesday.

Oct 27, 2026·2 sources
00

Ferring to acquire fertility startup Gameto for up to $1.38B

Ferring Pharmaceuticals has signed an agreement to acquire fertility startup Gameto in a deal worth up to $1.3825 billion, expanding its reproductive health portfolio.

Oct 27, 2026·2 sources
00

Cipla misses Q2 profit forecast on US weakness, shares slip

Indian drugmaker Cipla reported second-quarter earnings that missed profit expectations due to weakness in its US business, causing its shares to decline. The disappointing results reflect challenges in the company's American operations.

Oct 27, 2026·1 source
00

Novartis raises profit guidance despite $1.9 billion drug trial setback

Novartis increased its full-year core profit outlook for the third time in 2026, driven by growth of new medicines, but took a $1.9 billion write-down for neuromuscular drug candidate del-desiran following trial failure.

Oct 27, 2026·2 sources
00
Oct 26, 2026

GSK to nearly double cancer drugs in clinical trials by 2027

GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal interview with a company scientist. The expansion follows a dealmaking spree as the British drugmaker accelerates its return to oncology.

Oct 26, 2026·5 sources
00

Genmab's ovarian cancer drug cuts death risk 57% in late-stage trial

Genmab's experimental antibody-drug conjugate Rina-S reduced the risk of death by 57% compared to chemotherapy in patients with advanced ovarian cancer, according to phase 3 trial results presented at ESMO. The Danish drugmaker's shares surged over 12% on the news.

Oct 26, 2026·2 sources
00

Bayer wins China approval for stroke prevention drug asundexian

China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.

Oct 26, 2026·3 sources
00
Oct 25, 2026

AstraZeneca's sone-ve extends overall survival in advanced stomach cancer trial

AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.

Oct 25, 2026·2 sources
00
Oct 24, 2026

Amgen's Imdelltra combo cuts death risk 58% in small cell lung cancer trial

Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.

Oct 24, 2026·3 sources
00
Oct 23, 2026

Novartis multiple sclerosis drug remibrutinib shows weaker-than-expected relapse reduction

Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.

Oct 23, 2026·4 sources
00

Bristol Myers patient died after CAR-T treatment, company explains June trial pause

Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.

Oct 23, 2026·5 sources
00

UK approves Johnson & Johnson's oral psoriasis pill for moderate-to-severe plaque psoriasis

Britain's medicines regulator approved Johnson & Johnson's daily pill for adults and teenagers with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly and often itchy patches.

Oct 23, 2026·2 sources
00

Roche licenses Zymeworks' experimental lung cancer drug ZW209 in deal worth up to $813 million

Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.

Oct 23, 2026·5 sources
00

Star Therapeutics raises $200 million to advance pipeline after spinout successes

Star Therapeutics has secured $200 million in private financing to advance its preclinical programs into clinical trials and expand its pipeline. The funding follows the company's successful track record of spinning out companies including Vega and Electra, with Incyte acquiring one of its spinouts in July 2026.

Oct 23, 2026·5 sources
00
Oct 22, 2026

Gilead acquires PepStar inflammation drug program for $1.28 billion

Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.

Oct 22, 2026·3 sources
00
Oct 21, 2026

Roivant's brepocitinib succeeds in phase 3 trials for non-infectious uveitis

Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.

Oct 21, 2026·7 sources
00
Oct 20, 2026

FDA approves GSK's hepatitis B drug Hibsago

The FDA approved GSK's hepatitis B drug Hibsago, allowing patients with the liver infection to maintain viral control after stopping long-term treatment. The approval offers a new treatment option for chronic hepatitis B patients.

Oct 20, 2026·2 sources
00
Oct 19, 2026

Mirikizumab achieves clinical remission in pediatric ulcerative colitis phase 3 trial

Eli Lilly's mirikizumab (Omvoh) achieved clinical and endoscopic remission rates in children with ulcerative colitis that exceeded historical adult placebo outcomes at week 12 in the SHINE-2 phase 3 study. The positive pediatric data could provide a competitive advantage for the IL-23p19 inhibitor in the inflammatory bowel disease market.

Oct 19, 2026·3 sources
00
Oct 14, 2026

GSK to cut up to 1,217 jobs in Belgium as part of restructuring plan

GSK announced plans to make up to 1,217 workers redundant from its Belgian sites, marking the first major action in the drugmaker's three-year plan to save £1.9 billion in costs.

Oct 14, 2026·2 sources
00
Oct 12, 2026

Syndax Pharmaceuticals ends idiopathic pulmonary fibrosis program after phase 2 trial failure

Syndax Pharmaceuticals discontinued development of Niktimvo for idiopathic pulmonary fibrosis after a mid-stage trial failed to meet its primary endpoint. The company's shares fell 17% in extended trading following the announcement.

Oct 12, 2026·6 sources
00
Oct 8, 2026

Viatris to acquire Pacira BioSciences for $1.65 billion

Drugmaker Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in cash, expanding its portfolio of pain management therapies.

Oct 8, 2026·2 sources
00
Sep 28, 2026

Merck discontinues Recarbrio antibiotic despite concerns over superbug resistance

Merck has discontinued Recarbrio, a crucial antibiotic used to treat drug-resistant infections, raising concerns among health experts about the availability of treatments for superbug resistance at a time when antimicrobial resistance remains a growing public health threat.

Sep 28, 2026·2 sources
00

Kodiak Sciences' Zenkuda and KSI-501 meet primary endpoints in wet AMD phase 3 trial

Kodiak Sciences announced that both investigational therapies, Zenkuda (tarcocimab tedromer) and KSI-501, met their primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration, matching the performance of Regeneron's Eylea at one year. The company's stock surged over 65% in premarket trading following the announcement.

Sep 28, 2026·4 sources
00
Sep 22, 2026

Amgen's dazodalibep succeeds in Phase 3 trial for Sjögren's disease

Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe Sjögren's disease, a chronic autoimmune condition with no currently approved therapies. The drug was acquired through Amgen's $28 billion Horizon Therapeutics buyout.

Sep 22, 2026·4 sources
00

Vertex Pharmaceuticals reports positive phase 2b trial results for inaxaplin in kidney disease

Vertex Pharmaceuticals announced positive results from its phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD), including patients with modest proteinuria and those with type 2 diabetes. The company is positioning the drug for a broad kidney disease label ahead of a key readout next year.

Sep 22, 2026·6 sources
00

Novo Nordisk CEO says weight-loss pills could capture 50% of obesity market by 2030

Novo Nordisk CEO Mike Doustdar told Reuters that oral weight-loss medications could represent up to half of the global obesity drug market by 2030, as the Danish drugmaker positions itself for a shift toward pill-based treatments alongside its injectable GLP-1 drugs.

Sep 22, 2026·3 sources
00
Sep 21, 2026

Johnson & Johnson cuts 87 jobs in New Jersey workforce

Johnson & Johnson has laid off 87 employees from its New Jersey operations in 2026, marking another round of workforce reductions for the pharmaceutical giant in the state.

Sep 21, 2026·1 source
00
Sep 18, 2026

Trump demands drug companies split combined vaccines following Kennedy remarks

President Trump announced he will demand pharmaceutical companies separate combined vaccines into individual doses, one day after Health Secretary Robert F. Kennedy Jr. told an anti-vaccine conference that vaccine skeptics have a 'friend at the White House.'

Sep 18, 2026·2 sources
00
Sep 17, 2026

Judge approves CVS unit Omnicare's bankruptcy plan after $250 million sale

A Texas judge approved a wind-down bankruptcy plan for CVS Health subsidiary Omnicare LLC following the sale of its business operations for $250 million and resolution of a nearly $1 billion judgment related to improperly dispensing prescription drugs.

Sep 17, 2026·3 sources
00
Sep 14, 2026

Novo Nordisk rebrands to Novo, updates logo

Novo Nordisk announced it is shortening its corporate name to Novo and updating its logo as part of a rebranding effort amid competition in the obesity drug market.

Sep 14, 2026·2 sources
00
Sep 13, 2026

Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines

Pfizer is targeting air traffic control agencies in Poland and Romania to enforce a Belgian court ruling ordering the two countries to accept €1.9 billion worth of COVID-19 vaccines they refused to take delivery of after pandemic-era demand waned.

Sep 13, 2026·1 source
00
Sep 10, 2026

Takeda R&D chief Andy Plump to retire in June 2027

Andy Plump, who led Takeda's research and development overhaul and pushed the company toward biotech partnerships, will retire in June 2027 after celebrating two recent FDA approvals.

Sep 10, 2026·2 sources
00
Sep 8, 2026

Sandoz CEO warns Trump generic drug tariffs would raise costs for American patients

The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.

Sep 8, 2026·1 source
00

Sandoz CEO warns Trump generic drug tariffs would raise costs for American patients

The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.

Sep 8, 2026·1 source
00

AstraZeneca's experimental COPD drug shows strong results in late-stage trials

AstraZeneca released full results from two successful late-stage trials showing its experimental drug significantly reduced dangerous flare-ups in chronic obstructive pulmonary disease patients across a broad patient population, boosting the treatment's blockbuster potential.

Sep 8, 2026·8 sources
00
Sep 1, 2026

Alumis experimental lupus drug fails primary endpoint in phase 3 trial

Alumis reported its experimental TYK2 inhibitor failed to meet the main goal of a late-stage lupus trial, though the company plans to advance the drug in a smaller subset of patients.

Sep 1, 2026·2 sources
00

Kenya signs deal with Pfizer to cut cancer drug prices by more than seven times

The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.

Sep 1, 2026·1 source
00
Aug 28, 2026

Cytokinetics reports positive late-stage data for heart drug aficamten

Cytokinetics announced detailed late-stage trial results showing its drug aficamten significantly improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy, a genetic heart condition with no approved treatments.

Aug 28, 2026·2 sources
00
Aug 27, 2026

AstraZeneca and Amgen's Tezspire meets Phase 3 goals in eosinophilic esophagitis

Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially becoming the drug's third approved indication and positioning it to compete with Sanofi's Dupixent, currently the only approved biologic for the condition.

Aug 27, 2026·2 sources
00
Aug 26, 2026

White House to announce new drug pricing deals with biotech companies

The Trump administration plans to announce a new round of drug-pricing agreements with several midsized biotech companies on Monday, according to people familiar with the matter.

Aug 26, 2026·2 sources
00

Biohaven licenses epilepsy drug platform to SK Biopharmaceuticals for up to $795 million

Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.

Aug 26, 2026·2 sources
00
Aug 24, 2026

Bristol Myers ends blood cancer drug partnership with Cellares

Bristol Myers Squibb terminated its partnership with cell therapy startup Cellares to expand manufacturing of its personalized blood cancer therapy, prompting Cellares to lay off 100 employees.

Aug 24, 2026·2 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 18, 2026

Leo Pharma acquires worldwide rights to dersimelagon for up to $435M

Danish drugmaker Leo Pharma agreed to acquire worldwide rights to dersimelagon, a late-stage drug candidate for two rare genetic skin diseases, from Tanabe Pharma for up to $435 million in upfront and milestone payments.

Aug 18, 2026·2 sources
00
Aug 14, 2026

Two-thirds of new drugs launched above cost-effectiveness thresholds, ICER reports

A new ICER analysis found that net launch prices for new medicines spiked significantly between 2022 and 2025, with two-thirds of new drugs priced above cost-effectiveness guidelines. About a quarter of drugs launched in the most recent year had annual net prices exceeding $500,000.

Aug 14, 2026·5 sources
00
Aug 13, 2026

Grifols pauses plasma collection at Canadian clinics after two donor deaths

Spanish pharmaceutical company Grifols has temporarily halted plasma donations at all 16 of its Canadian clinics following the deaths of two donors and a government investigation into potential unsafe practices at the for-profit facilities.

Aug 13, 2026·3 sources
00

Taiho and Cullinan's zipalertinib succeeds in phase 3 lung cancer trial

Taiho Oncology and Cullinan Therapeutics announced their next-generation EGFR inhibitor zipalertinib significantly improved progression-free survival in a registrational phase 3 trial for first-line treatment of advanced non-small cell lung cancer. The results position the drug as a competitor to multiple approved medicines in the EGFR-mutated lung cancer market.

Aug 13, 2026·4 sources
00
Aug 10, 2026

Hims & Hers posts wider loss as shift to branded weight-loss drugs drives up costs

Hims & Hers Health reported a wider-than-expected second-quarter loss as the telehealth company's shift to branded weight-loss drugs drove up costs, sending shares down 6% in extended trading. The company plans to enter the peptides market before year-end.

Aug 10, 2026·3 sources
00

Sionna Therapeutics halts cystic fibrosis drug development after trial failure

Sionna Therapeutics discontinued development of its experimental cystic fibrosis pill after it failed to show meaningful benefit when added to standard treatment in a mid-stage trial, causing shares to plunge.

Aug 10, 2026·2 sources
00

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32 Billion in Rare Epilepsy Deal

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.

Aug 10, 2026·6 sources
00
Aug 6, 2026

Texas Federal Court Dismisses Antitrust Lawsuit Against Eli Lilly and Novo Nordisk Filed by Compounding Pharmacy

A Texas federal judge has dismissed an antitrust lawsuit brought by compounding pharmacy Strive Specialties Inc. against pharmaceutical companies Eli Lilly and Novo Nordisk.

Aug 6, 2026·1 source
00

Tarsus Pharmaceuticals to Acquire Alkeus for Up to $800M, Gaining Late-Stage Stargardt Disease Drug

Tarsus Pharmaceuticals agreed to acquire privately-held Alkeus Pharmaceuticals for $450 million upfront and up to $800 million total, gaining gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease. The rare genetic eye condition affects over 36,000 people in the U.S. and currently has no FDA-approved treatment, with pivotal trial data expected in late 2029.

Aug 6, 2026·5 sources
00
Aug 4, 2026

Otsuka's VOYXACT Shows Kidney Function Stabilization in Phase 3 Trial; BioNTech Cuts Revenue Forecast on Weak COVID Vaccine Demand

Otsuka announced two-year Phase 3 VISIONARY trial results showing VOYXACT (sibeprenlimab-szsi) stabilized kidney function decline in IgA nephropathy patients, with annual eGFR slope of +0.3 versus -4.2 for placebo. Separately, BioNTech lowered its 2026 revenue guidance by €400 million to €1.6-1.9 billion due to declining COVID-19 vaccine demand.

Aug 4, 2026·6 sources
00

Novo Nordisk shares slide despite beating quarterly estimates

Novo Nordisk reported quarterly results that beat expectations and raised guidance, but shares fell as investors remained concerned about the company's path to sustainable growth amid increasing competition in the obesity drug market.

Aug 4, 2026·2 sources
00

Pfizer beats revenue estimates on strength of Eliquis and other drugs

Pfizer reported second-quarter revenue that exceeded analyst expectations, driven by strong sales of blood thinner Eliquis and other key medications. The company raised the low end of its full-year revenue guidance.

Aug 4, 2026·1 source
00

Merck's anti-TL1A antibody shows mixed Phase 2 results in hidradenitis suppurativa and lung disease

Merck's anti-TL1A antibody from its 2023 Prometheus Biosciences acquisition delivered positive mid-stage results in hidradenitis suppurativa but failed to meet endpoints in a rare lung disease trial. The company disclosed the mixed Phase 2 results alongside its second-quarter earnings.

Aug 4, 2026·2 sources
00

Merck raises 2026 sales outlook on strength of newer drugs including Winrevair

Merck beat second-quarter estimates and boosted its 2026 sales forecast after strong demand for newer drugs like Winrevair helped drive revenues higher, though the company cut profit guidance due to deal-related charges.

Aug 4, 2026·2 sources
00
Aug 3, 2026

Curium to take radiopharma company Lantheus private in $8 billion deal

Nuclear medicine company Curium has struck a deal to take Lantheus Holdings Inc. private in a transaction worth approximately $8 billion.

Aug 3, 2026·2 sources
00

Supernus Pharmaceuticals and Indivior Pharmaceuticals Agree to All-Stock Merger Creating $2.2 Billion CNS Drug Company

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger to create a combined company with approximately $2.2 billion in annual revenue and a portfolio of 11 commercialized medicines focused on neurological, psychiatric, and addiction-related conditions. The deal, described as a merger of equals, is expected to generate $125 million in cost savings.

Aug 3, 2026·9 sources
00
Aug 2, 2026

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal

AstraZeneca is reportedly in discussions with Bristol Myers Squibb regarding a potential $400 billion merger, which would create one of the largest pharmaceutical companies globally and reshape the cancer treatment industry.

Aug 2, 2026·1 source
00
Jul 17, 2026

GSK halts development of chronic cough drug after late-stage trial failures

GSK discontinued development of an experimental chronic cough treatment after it failed to meet key goals in two late-stage clinical trials, with the company stating it was unlikely to transform patient care. Shares fell about 4%.

Jul 17, 2026·2 sources
00
Jul 9, 2026

Moderna Wins EU Contract for RSV Vaccine Supply

Moderna has secured a contract with the European Union to supply its respiratory syncytial virus (RSV) vaccine, expanding the company's vaccine portfolio beyond COVID-19.

Jul 9, 2026·1 source
00
Jun 29, 2026

Roche Launches Axelios Gene Sequencer to Challenge Illumina's Market Dominance

Swiss pharmaceutical giant Roche launched its long-awaited Axelios gene sequencer, aiming to break Illumina's leadership position in the next-generation sequencing market.

Jun 29, 2026·1 source
00
Jun 26, 2026

European Medicines Agency Recommends Revoking Amgen's Tavneos Over Data Integrity Issues

The European Medicines Agency recommended withdrawing marketing authorization for Amgen's rare autoimmune disease drug Tavneos, citing allegedly incorrect and misleading data used in the approval process and lack of benefits outweighing risks.

Jun 26, 2026·3 sources
00
Jun 20, 2026

Sun Pharma Acquires Innovcare Lifesciences for $28.7 Million

Indian pharmaceutical company Sun Pharma announced the acquisition of Innovcare Lifesciences for $28.7 million, expanding its portfolio in the specialty pharmaceutical sector.

Jun 20, 2026·1 source
00
May 28, 2026

CVS Health Restores Coverage of Eli Lilly's Zepbound and Adds New Obesity Pill to Drug Plans

CVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option and begin coverage for the drugmaker's newly approved obesity pill, Forza.

May 28, 2026·2 sources
00
May 18, 2026

Trump Invested in Eli Lilly Stock as Administration Boosted Obesity Drug Policies

New ethics disclosures reveal President Trump purchased stock in Eli Lilly and an injectable device manufacturer while his health agencies implemented policies benefiting these companies' obesity drug products.

May 18, 2026·1 source
00
May 13, 2026

Optum Rx Replaces Traditional PBM Model with Flat Fee-Based Structure

Optum Rx announced it will transition away from the traditional pharmacy benefit manager model to a flat service fee structure, with group purchasing fully converting to flat fees by end of 2027.

May 13, 2026·1 source
00
May 5, 2026

Cytokinetics' Heart Disease Drug Myqorzo Meets Primary Endpoints in Phase 3 Trial for Genetic Heart Condition

Cytokinetics announced its heart disease drug Myqorzo, already approved in one indication, succeeded in meeting twin efficacy goals in a Phase 3 trial for genetic heart disease, potentially boosting future sales.

May 5, 2026·1 source
00

UCB Acquires Maker of Antibody Treatments for Autoimmune Diseases

Belgian pharmaceutical company UCB has announced the acquisition of a company specializing in antibody treatments for autoimmune diseases, expanding its immunology portfolio.

May 5, 2026·1 source
00
May 3, 2026

Eli Lilly Raises 2026 Guidance as GLP-1 Drug Demand Surges in Q1

Eli Lilly reported strong Q1 2026 financial results driven by massive growth in Mounjaro and Zepbound sales, leading the company to raise its full-year guidance amid surging demand for GLP-1 medications.

May 3, 2026·1 source
00
May 1, 2026

U.S. prescription drug spending projected to exceed $1 trillion in 2026, driven by weight-loss medications

Americans are expected to spend more than $1 trillion on prescription drugs in 2026, according to a new report from the American Society of Health-System Pharmacists. The surge is largely attributed to the growing popularity of GLP-1 weight-loss drugs.

May 1, 2026·3 sources
00
Apr 29, 2026

AstraZeneca Commits $405M to UK Expansion Following US-UK Pharma Deal

AstraZeneca commits $405 million to expand operations in the United Kingdom following a new US-UK pharma agreement, signaling increased investment and strategic alignment across transatlantic drug markets.

Apr 29, 2026·2 sources
00
Feb 17, 2026

Republicans and Democrats unite to target pharmacy benefit managers with new regulations

Bipartisan efforts are emerging at federal and state levels to regulate pharmacy benefit managers (PBMs), with proposals including barring companies from owning both PBMs and retail pharmacies. Two states have already enacted such restrictions, while federal legislation has gained support from both conservative Republicans and progressive Democrats.

Feb 17, 2026·4 sources
00

Top claims

  • ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer
  • ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
  • ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies

People involved

Vinay PrasadDonald TrumpRobert F. Kennedy Jr.Michael SenaWilliam Ruto

Subtopics

Drug Policy, Pricing & Approval38Pharma37Clinical trials33Drug development26Cancer & Oncology20Drug Approval and Clinical Trials20Mergers & acquisitions (M&A)15Corporate earnings11Corporate strategy10Eli Lilly10FDA drug approval10Pharmaceutical earnings9Rare diseases9Autoimmune disease treatments8Biotechnology8Cancer treatment8Clinical Trial Design & Evaluation8Novo Nordisk8Biotech innovation7Drug safety7Medication Pricing & Affordability7Mergers and acquisitions7Cancer immunotherapy6Clinical evaluation6

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories